SCHEMBL6370428

SCHEMBL6370428

CC(C)(C)OC(=O)n1nc(-c2ccccc2)c2ccc(Nc3ccc(F)cc3)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.42
MAPT P10636 3/20 0.39
PTGER1 P34995 2/20 0.39
TP53 P04637 2/20 0.38
DGAT2 Q96PD7 6/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
JAK2 O60674 3/20 0.37
JAK3 P52333 2/20 0.37
PTK2 Q05397 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6370068 0.94 MAP2K4 (0.48) MAP2K4ABCG2MAPTPTGER1KDM4E
SCHEMBL6370616 0.90 MAP2K4 (0.57) MAP2K4ABCG2MAPTPTGER1JAK2
SCHEMBL6370071 0.88 MAP2K4 (0.46) MAP2K4ABCG2MAPTPTGER1KDM4E
SCHEMBL6375104 0.86 MAP2K4 (0.58) MAP2K4ABCG2MAPTPTGER1TP53
SCHEMBL6375165 0.86 PTGER1 (0.51) MAP2K4ABCG2MAPTPTGER1KDM4E
SCHEMBL6370625 0.85 MAPK8 (0.51) MAP2K4MAPTPTGER1TP53KDM4E
SCHEMBL6369989 0.85 MAP2K4 (0.43) MAP2K4MAPTPTGER1KDM4EALDH1A1
SCHEMBL6370211 0.84 MAP2K4 (0.44) MAP2K4PTGER1TP53KDM4EALDH1A1
SCHEMBL6369555 0.84 MAPK8 (0.47) MAP2K4MAPTPTGER1ACHEBACE1
SCHEMBL6369571 0.82 MAP2K4 (0.45) MAP2K4PTGER1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 MAP2K4 2785/4885ABCG2 838/4885MAPT 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.